Cargando…

Real-World Experience of Chronic Hepatitis C-Related Compensated Liver Cirrhosis Treated with Glecaprevir/Pibrentasvir: A Multicenter Retrospective Study

Background: Glecaprevir/pibrentasvir is a protease inhibitor-containing pangenotypic direct-acting antiviral regimen that has been approved for the treatment of chronic hepatitis C. The present study aimed to evaluate the safety and efficacy of glecaprevir/pibrentasvir in patients with compensated c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Pei-Yuan, Chen, Yang-Yuan, Lai, Jun-Hung, Chen, Hung-Ming, Yao, Chih-Ta, Liu, I-Ling, Zeng, Ya-Huei, Huang, Siou-Ping, Hsu, Yu-Chun, Wu, Shun-Sheng, Siao, Fu-Yuan, Yen, Hsu-Heng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8619604/ https://www.ncbi.nlm.nih.gov/pubmed/34830518 http://dx.doi.org/10.3390/jcm10225236

Ejemplares similares

Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting
por: Yen, Hsu-Heng, et al.
Publicado: (2020)

Comparison of 8- versus 12-weeks of glecaprevir/pibrentasvir for Taiwanese patients with hepatitis C and compensated cirrhosis in a real-world setting
por: Lu, Yung-Hsin, et al.
Publicado: (2022)

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
por: Chang, Te-Sheng, et al.
Publicado: (2023)

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis
por: Yoon, Jae Hyun, et al.
Publicado: (2019)

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
por: Reau, Nancy, et al.
Publicado: (2023)

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
por: Cornberg, Markus, et al.
Publicado: (2022)

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
por: Yap, Desmond Y. H., et al.
Publicado: (2020)

Japanese Man with HCV Genotype 4 Infection and Cirrhosis Who Was Successfully Treated by the Combination of Glecaprevir and Pibrentasvir
por: Totsuka, Mai, et al.
Publicado: (2021)

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
por: Liu, Xiaoqing, et al.
Publicado: (2021)

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
por: Flamm, Steven L., et al.
Publicado: (2020)

Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
por: Sugiura, Ayumi, et al.
Publicado: (2020)

Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
por: Yamana, Yoichiro, et al.
Publicado: (2021)

Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver Disease
por: Gane, Edward, et al.
Publicado: (2019)

Pan-Genotypic Direct-Acting Antiviral Agents for Undetermined or Mixed-Genotype Hepatitis C Infection: A Real-World Multi-Center Effectiveness Analysis
por: Yen, Hsu-Heng, et al.
Publicado: (2022)

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
por: Chayama, Kazuaki, et al.
Publicado: (2017)

Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis
por: Jain, Ayushi, et al.
Publicado: (2022)

Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis
por: Hung, Hsuan-Yu, et al.
Publicado: (2021)

Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
por: Aghemo, Alessio, et al.
Publicado: (2021)

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts
por: Feld, Jordan J., et al.
Publicado: (2022)

The efficacy and tolerability of glecaprevir/pibrentasvir treatment in a real-world chronic hepatitis C patients cohort
por: Yaras, Serkan, et al.
Publicado: (2023)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
por: Cotter, Thomas G, et al.
Publicado: (2019)

Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid
por: Tamai, Hideyuki, et al.
Publicado: (2023)

Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir
por: Aghemo, Alessio, et al.
Publicado: (2021)

Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts
por: Forns, Xavier, et al.
Publicado: (2021)

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
por: Reau, Nancy, et al.
Publicado: (2018)

Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial
por: Madsen, Lone W., et al.
Publicado: (2022)

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension
por: Brown, Robert S., et al.
Publicado: (2022)

Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
por: Arora, Rishi, et al.
Publicado: (2023)

Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
por: Wyles, David, et al.
Publicado: (2018)

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection
por: Naganuma, Atsushi, et al.
Publicado: (2019)

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis
por: Back, David, et al.
Publicado: (2019)

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study
por: Jonas, Maureen M., et al.
Publicado: (2021)

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
por: Zamor, Philippe J., et al.
Publicado: (2021)

Acute Kidney Injury Presenting as Hepatorenal Syndrome in the Setting of Glecaprevir/Pibrentasvir Treatment for Hepatitis C
por: Fansiwala, Kush, et al.
Publicado: (2021)

High Real-World Sustained Virologic Response Rate with Glecaprevir/Pibrentasvir at a Racially Diverse Urban Academic Medical Center
por: Martin, Michelle T., et al.
Publicado: (2022)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studies
por: Yao, Betty B., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8073aliq6slotve5ma4s85t0r1